FIELD: biotechnology; medicine; agriculture.
SUBSTANCE: invention refers to genetic engineering and can be used in biotechnology, medicine and agriculture to develop gene therapy preparations. Gene-therapeutic DNA vector based on a genotyping DNA vector GDTT1.8NAS12, wherein the gene-therapeutic DNA vector GDTT1.8NAS12-IFNB1 contains a coding portion of the desired IFNB1 gene cloned into the genotyping DNA vector GDTT1.8NAS12, with the nucleotide sequence SEQ ID No. 1, gene-therapeutical DNA vector GDTT1.8NAS12-IFNA14 contains a coding part of the target IFNA14 gene cloned into a genotyping DNA vector GDTT1.8NAS12, with the nucleotide sequence SEQ ID No. 2, gene-therapeutic DNA vector GDTT1.8NAS12-IFNA2 contains a coding part of the target IFNA2 gene cloned into a genotyping DNA vector GDTT1.8NAS12, with the nucleotide sequence SEQ ID No. 3, gene-therapeutic DNA vector GDTT1.8NAS12-IL12A contains a coding part of the target gene IL12A, cloned into a genotyping DNA vector GDTT1.8NAS12, with the nucleotide sequence SEQ ID No. 4, gene-therapeutic DNA vector GDTT1.8NAS12-IL12B contains a coding part of the target gene IL12B, cloned into a genotyping DNA-vector GDTT1.8NAS12, with a nucleotide sequence SEQ ID No.5.
EFFECT: treating the diseases characterized by congenital and adaptive immunity disorders for the therapy of autoimmune, oncological, viral diseases associated with immune system imbalance, for immunomodulation including in anticancer vaccination as a gene therapeutic adjuvant.
16 cl, 17 dwg, 23 ex
